Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicohort, Single-Centre, Phase II Trial of the Efficacy and Safety of Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer

NCT06146985 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT06146985
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06146985 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicohort, Single-Centre, Phase II Trial of the Efficacy and Safety of Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer
Lead sponsor
Ruijin Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
December 1, 2023
Completion date
May 1, 2025
Enrollment
67 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid cancer